8legs: Moleculin biotech, inc.

#1 out of 1

Moleculin Presents ASCO Data Showing No Detectable Cardiotoxicity with Annamycin at High Exposure

Moleculin reports pooled ASCO data showing no detectable cardiotoxicity from Annamycin at high exposure.
In 90 patients, LVEF change was not significant (mean diff -0.12%).
No correlation found between cumulative Annamycin dose and LVEF changes.
Independent Cleveland Clinic review found no evidence of drug-induced cardiotoxicity.
Phase 1b/2 AML results show favorable responses reinforcing MIRACLE trial rationale.
The data come from ASCO presentations and SEC filings about Moleculin Biotech, Inc.
The summary is AI-generated and should be verified against the source.
Cumulative dose exposure reached a median of 660 mg/m² in the analysed cohort.
The ASCO data included 78 patients with paired LVEF measurements.
The study found no significant LVEF change despite high exposure, supporting safety signals.

Vote 0